Darovasertib (LXS196): Mechanism of Action

Darovasertib (LXS196) MOA:Targeting PKC/MAPK for Uveal Melanoma

🎯 check Darovasertib (LXS196) product page

Darovasertib (LXS196) is a potent, selective PKC inhibitor. It affects PKC signaling, by blocking kinase activity, inhibiting uveal melanoma (UM) progression, and is safely evaluated in combination with crizotinib.

Primary Applications and Mechanism of Action